Skip to main content

Market Overview

Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder

Share:
Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder
  • Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD).
  • The target action date is set at August 22.
  • AXS-05 (dextromethorphan-bupropion) is an oral, investigational NMDA receptor antagonist with multimodal activity.
  • Priority Review designation accelerates the review time from 10 months to a goal of six months from the date of acceptance of the filing.
  • The FDA had previously granted Breakthrough Therapy Designation for AXS-05 to treat MDD and Alzheimer's disease agitation.
  • The NDA is supported by results from two trials, the GEMINI and ASCEND, which demonstrated statistically significant improvements in depressive symptoms with AXS-05 compared to placebo and active controls.
  • Price Action: AXSM shares are up 12.9% at $59.7 in the premarket trading on the last check Monday.
 

Related Articles (AXSM)

View Comments and Join the Discussion!

Posted-In: Briefs depressionBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com